soul trial oral semaglutide cardiovascular outcomes nejm 2025 results In the OASIS 4 phase 3 trial, once-daily at a dose of 25 mg resulted in a greater mean reduction in body weight than placebo in participants with overweight or PDF) Oral Semaglutide and Cardiovascular
Pay in 4 interest-free payments of $6.35 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2












:format(webp))












